New antithrombotic drugs and European approval processes

Lancet. 2011 Aug 20;378(9792):662-3. doi: 10.1016/S0140-6736(11)61327-5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anticoagulants / therapeutic use
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Dabigatran
  • Drug Approval*
  • Europe
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Morpholines / adverse effects
  • Morpholines / therapeutic use*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Pyridones / adverse effects
  • Pyridones / therapeutic use*
  • Rivaroxaban
  • Thiophenes / adverse effects
  • Thiophenes / therapeutic use*
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / therapeutic use

Substances

  • Anticoagulants
  • Benzimidazoles
  • Fibrinolytic Agents
  • Morpholines
  • Pyrazoles
  • Pyridones
  • Thiophenes
  • beta-Alanine
  • apixaban
  • Rivaroxaban
  • Dabigatran